Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant herpes simplex virus type 2 vaccine (Beijing Luzhu Biotechnology)
- Development stage
- Preclinical
- Lead developer
- Beijing Luzhu Biotechnology
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
The recombinant herpes simplex virus type 2 (HSV-2) vaccine is a preclinical-stage candidate being developed by Beijing Luzhu Biotechnology for the prevention of genital herpes. As a recombinant protein vaccine, it is designed to elicit a protective immune response by introducing specific HSV-2 antigens produced through recombinant DNA technology. This asset is part of Beijing Luzhu's broader pipeline of recombinant vaccines, which includes their lead candidate LZ901 for shingles. The development of this vaccine addresses the significant global burden of genital herpes, for which no highly effective preventive vaccine is currently available.
- Other names
- HSV-2 recombinant protein vaccineHSV2 recombinant protein vaccineHSV 2 recombinant protein vaccineBeijing Luzhu HSV-2 vaccine
Beyond the preview
Go deeper on recombinant herpes simplex virus type 2 vaccine (Beijing Luzhu Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant herpes simplex virus type 2 vaccine (Beijing Luzhu Biotechnology).